Abstract:Objective: To investigate the role of the glycogen synthase kinase 3β (GSK3β) and the peroxisome proliferator-activated receptor alpha (PPARα) signaling pathway in acute liver failure and related mechanisms in a mouse model of acute liver failure induced by D-galactosamine/lipopolysaccharide (D-GalN/LPS). Methods: C57BL/6 mice were given intraperitoneal injection of D-GalN/LPS to establish a mouse model of acute liver failure. SB216763 was used to inhibit the activity of GSK3β and PPARα siRNA was used to inhibit the expression of PPARα. Western blotting was used to measure the expression of PPARα protein. The changes in liver pathology were observed to evaluate liver injury, and the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured to assess liver function. Quantitative real-time PCR was used to measure the mRNA expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-12p40 (IL-12p40), and PPARα. A one-way analysis of variance was used for comparison of means between multiple groups; the least significant difference test was used for data with homogeneity of variance, and the Games-Howell method was used for data with heterogeneity of variance. Results: In the mice with liver failure induced by D-GalN/LPS, GSK3β inhibition promoted the mRNA and protein expression of PPARα (F = 13.18 and 301.36, P = 0.00 and 0.00). In the mice with acute liver failure induced by D-GalN/LPS, GSK3β inhibition alleviated liver bleeding, inflammation, and necrosis and reduced the serum levels of ALT (F = 25.16, P = 0.000) and AST (F = 12.96, P = 0.001), as well as the mRNA expression of TNF-α (F = 32.17, P = 0.00), IL-1β (F = 11.57, P = 0.005), and IL-12p40 (F = 14.17, P = 0.015) in liver tissue. The inhibition of PPARα expression reversed the liver-protecting effect of GSK3β inhibition, which manifested as aggravation in liver bleeding, inflammation, and necrosis, increases in the serum levels of ALT (F = 25.16, P = 0.001) and AST (F = 12.96, P = 0.000), and an increase in the mRNA expression of TNF-α (F = 32.17, P = 0.00), IL-1β (F = 11.57, P = 0.024), and IL-12p40 (F = 14.17, P = 0.001) in liver tissue. Conclusion: In mice with acute liver failure induced by D-GalN/LPS, the GSK3β-PPARα-inflammatory factor signaling pathway may play an important role. GSK3β inhibition has a protective effect in mice with acute liver failure possibly by activating the inhibitory inflammatory factor of PPARα.

Silencing of GDF11 suppresses hepatocyte apoptosis to relieve LPS/D‐GalN acute liver failure

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

SINGLE NUCLEOTIDE POLYMORPHISM IN IFN WAS ASSOCIATED WITH ACUTE REJECTION AFTER LIVER TRANSPLANTATION

Isoliquiritigenin Alleviates LPS/ D-GalN-induced Acute Liver Failure by Activating the PGC-1α/ Nrf2 Pathway to Reduce Oxidative Stress and Inflammatory Response.

Tectorigenin Protects Against Experimental Fulminant Hepatic Failure by Regulating the TLR4/mitogen‐activated Protein Kinase and TLR4/nuclear Factor‐κb Pathways and Autophagy

[Protective effect of glycogen synthase kinase 3β inhibition via peroxisome proliferator-activated receptor alpha activation in mice with acute liver failure].

Inhibition Of Glycogen Synthase Kinase 3 Beta Ameliorates D-Galn/Lps-Induced Liver Injury By Reducing Endoplasmic Reticulum Stress-Triggered Apoptosis

The role of TNF-α in the mechanism of D-GalN/LPS-induced acute liver failure

HIF-1α inhibition in macrophages preserves acute liver failure by reducing IL-1β production

Long-term expanded hepatic progenitor cells ameliorate D-GalN/LPS-induced acute liver failure through repolarizing M1 macrophage to M2-Like phenotype via activation of the IL-10/JAK2/STAT3 signaling pathway

Oral administration of grape-derived nanovesicles for protection against LPS/D-GalN-induced acute liver failure

Inhibition of the Translocation and Extracellular Release of High-Mobility Group Box 1 Alleviates Liver Damage in Fibrotic Mice in Response to D-galactosamine/lipopolysaccharide Challenge

Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators

Protective effect of glycogen synthase kinase 3β inhibitor TDZD-8 on liver injuries in mice with D-Gal/LPS-induced acute liver failure

Daphnetin alleviates lipopolysaccharide/d-galactosamine-induced acute liver failure via the inhibition of NLRP3, MAPK and NF-κB, and the induction of autophagy

Inhibiting the expression of hepatocyte nuclear factor 4 alpha attenuates lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice.

A20 Rescues Hepatocytes from Apoptosis Through the NF-κB Signaling Pathway in Rats with Acute Liver Failure.

Gasdermin D-mediated Hepatocyte Pyroptosis Expands Inflammatory Responses That Aggravate Acute Liver Failure by Upregulating Monocyte Chemotactic Protein 1/CC Chemokine Receptor-2 to Recruit Macrophages.

Endotoxin tolerance ameliorates lipopolysaccharide/D-galactosamine-induced acute liver failure by negative regulation of the NF-κB/NLRP3 and activation of Nrf2/HO-1 via Sitr1

[Effects of Granulocyte Colony-Stimulating Factor on Hepatocyte Apoptosis in Acute Liver Failure: Experiment with Rats].

Suppression of TNF-α and JNK- related pro-apoptotic signaling expression of oridonin in mice with LPS/D-Gal-induced acute liver failure